New hope for kids: drug may prevent transplant complications
NCT ID NCT06995521
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children and young adults (ages 1-26) with non-cancerous blood disorders who are getting a bone marrow transplant. GVHD is a serious complication where donor cells attack the patient's body. The trial will enroll 55 participants and measure how many are alive and free of GVHD one year after transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a skin biopsy reveal how axatilimab fights scarring in chronic GVHD?
- Could a breath test replace blood draws for metabolic disease monitoring?
- New transplant method aims to reduce complications in bone marrow failure patients
- New drug shows promise in controlling transplant complications
- New vitamin supplements aim to make life easier for kids with rare metabolic disorders
- New drug combo aims to make bone marrow transplants safer for kids